Titan Pharmaceuticals, Inc.
TTNP
$3.70
-$0.09-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -66.25% |
| Gross Profit | -- | -- | -- | -- | 63.16% |
| SG&A Expenses | -53.88% | -54.05% | 68.76% | -13.86% | 12.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.51% | -63.49% | 24.12% | -40.78% | -29.32% |
| Operating Income | 65.51% | 63.42% | -30.60% | 37.36% | 26.04% |
| Income Before Tax | 59.90% | -125.74% | -31.97% | 36.72% | 23.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.90% | -125.74% | -31.97% | 36.72% | 23.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.90% | -125.74% | -31.97% | 36.72% | 23.23% |
| EBIT | 65.51% | 63.42% | -30.60% | 37.36% | 26.04% |
| EBITDA | 65.46% | 62.93% | -33.70% | 35.85% | 24.86% |
| EPS Basic | 66.88% | -85.47% | -8.43% | 44.28% | 25.43% |
| Normalized Basic EPS | 67.26% | 69.72% | -8.43% | 44.28% | 24.56% |
| EPS Diluted | 66.88% | -85.47% | -8.43% | 44.28% | 25.43% |
| Normalized Diluted EPS | 67.26% | 69.72% | -8.43% | 44.28% | 24.56% |
| Average Basic Shares Outstanding | 21.06% | 21.70% | 21.70% | 13.58% | 2.95% |
| Average Diluted Shares Outstanding | 21.06% | 21.70% | 21.70% | 13.58% | 2.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |